| Bioactivity | SD-6 is an orally active inhibitor of hAChE and hBChE with IC50 values of 0.907 µM and 1.579 µM, respectively. SD-6 has excellent blood-brain barrier (BBB) permeability and no neurotoxicity, which can be used for research on Alzheimer's disease[1]. |
| Invitro | SD-6 (5-80 µM；24 h) 在 SH-SY5Y 细胞中具有神经保护作用[1]。 Cell Viability Assay[1] Cell Line: |
| In Vivo | SD-6 (100、300 和 500 mg/kg；口服；单剂量) 对未怀孕的雌性 Wistar 大鼠没有毒性作用[1]。SD-6 (2.5、5 和 10 mg/kg；口服；一天 3 次，持续 7 天) 改善了东莨菪碱 (HY-N0296) 诱导的雄性 Wistar 大鼠认知和记忆缺陷[1]。SD-6 (2.5、5 和 10 mg/kg；口服；单剂量) 显著改善了大鼠中东莨菪碱诱导的异常，促进生化指标正常化[1]。 Animal Model: |
| Name | SD-6 |
| CAS | 744206-31-3 |
| Formula | C20H22N4OS |
| Molar Mass | 366.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Waiker DK, et al. Development and Evaluation of Some Molecular Hybrids of N-(1-Benzylpiperidin-4-yl)-2-((5-phenyl-1,3,4-oxadiazol-2-yl)thio) as Multifunctional Agents to Combat Alzheimer's Disease. ACS Omega. 2023 Mar 2;8(10):9394-9414. |